stockrowSolid Biosciences Inc.
SLDB Healthcare Biotechnology
Solid Biosciences Inc.’s revenue for fiscal 2022 (year ended December 2022) was $8.1 million.
- EPS
- +25.6%
- Free cash flow
- −39.6%
Quarter to September 2026, against a year earlier
Follow SLDB
Alert me
Solid Biosciences Inc. (SLDB) EV/Sales
As of 6 November 2026, Solid Biosciences Inc. (SLDB) trades at a EV/Sales of 57.2×. Over the past ten years it has ranged from −16.1× (March 2023) to 109× (July 2026); the current reading is higher than 97% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | −14.6× | — |
| FY2021 | −1.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2022 | −14.6× | — |
| Jun 2022 | −4.7× | — |
| Mar 2022 | −3.7× | — |
| Dec 2021 | −1.5× | — |
| 3 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SANA Sana Biotechnology, Inc. compare | n/m |
| SGMT Sagimet Biosciences Inc. compare | n/m |
| ATTO Attovia Therapeutics, Inc. compare | n/m |
| AURA Aura Biosciences, Inc. compare | n/m |
| CGEM Cullinan Therapeutics, Inc. compare | n/m |
| WVE WAVE Life Sciences Ltd. compare | 3.6× |
| DNA Ginkgo Bioworks Holdings, Inc. compare | 4.0× |
| ACHV Achieve Life Sciences, Inc. compare | 29.0× |
| SLDB Solid Biosciences Inc. | 57.2× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)